Aβ-Immunotherapeutic strategies: A wide range of approaches for Alzheimer’s disease treatment

Expert Reviews in Molecular Medicine

Volumn 18, Issue , 2016, Pages

  Montoliu Gaya, Laia ^a   Villegas, Sandra ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG DEVELOPMENT; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG DISCOVERY; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME;

EID: 84976552907     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/erm.2016.11     Document Type: Review

References (132)

1. Alzheimer’s Disease International. (2014) World Alzheimer Report 2014: Dementia and Risk Reduction
2. Alzheimer’s Disease International. (2013) World Alzheimer Report 2013: Journey of Caring.
3. Sperling R.A. et al. (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimer’s & Dementia 7, 280-292
4. Albert M.S. et al. (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimer’s & Dementia 7, 270-279 doi:10.1016/j.jalz.2011.03.008
5. McKhann G.M. et al. (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia 7, 263-269
6. Yang T. et al. (2015) A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid. Alzheimer’s Research and Therapy 7, 14 doi:10.1186/s13195-015-0100-y
7. Terry R.D. et al. (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Annals of Neurology 30, 572-580 doi: 10.1002/ana.410300410
8. Benilova I., Karran E. and De Strooper B. (2012) The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nature Neuroscience 15, 349-357
9. Hardy J. and Selkoe D.J. (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353-356 doi:10.1126/science.1072994
10. Mawuenyega K.G. et al. (2010) Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science 330, 1774 doi: 10.1126/science.1197623
11. Bu G. (2009) Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nature Reviews Neuroscience 10, 333-344 doi:10.1038/nrn2620
12. Liu C.-C. et al. (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology 9, 106-118 doi:10.1038/nrneurol.2012.263
13. Kanekiyo T., Xu H. and Bu G. (2014) ApoE and Aβ in Alzheimer’s disease: accidental encounters or partners? Neuron 81, 740-754 doi:10.1016/j.neuron.2014.01.045
14. Huang Y. and Mucke L. (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222 doi:10.1016/j.cell.2012.02.040
15. Solomon B. (2009) Immunotherapeutic strategies for Alzheimer’s disease treatment. The Scientific World Journal 9, 909-919
16. Karran E., Mercken M. and De Strooper B. (2011) The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nature Reviews Drug Discovery 10, 698-712
17. Wolfe M.S. et al. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 398, 513-517 doi:10.1038/19077
18. Kojro E. and Fahrenholz F. (2005) The non-amyloidogenic pathway: structure and function of α-secretases. Subcellular Biochemistry 38, 105-127
19. Haass C. et al. (1993) Beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. Journal of Biological Chemistry 268, 3021-3024
20. LaFerla F.M., Green K.N. and Oddo S. (2007) Intracellular amyloid-β in Alzheimer’s disease. Nature Reviews Neuroscience 8, 499-509 doi:10.1038/nrn2168
21. Jarrett J.T., Berger E.P. and Lansbury P.T. (1993) The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry 32, 4693-4697
22. Younkin S.G. (1998) The role of Aβ42 in Alzheimer’s disease. Journal of Physiology – Paris 92, 289-292
23. Yamada M. (2015) Cerebral amyloid angiopathy: emerging concepts. Journal of Stroke 17, 17-30 doi:10.5853/jos.2015.17.1.17
24. Bentahir M. et al. (2006) Presenilin clinical mutations can affect γ-secretase activity by different mechanisms. Journal of Neurochemistry 96, 732-742 doi:10.1111/j.1471-4159.2005.03578.x
25. Wang J. et al. (1999) The levels of soluble versus insoluble brain Aβ distinguish Alzheimer’s disease from normal and pathologic aging. Experimental Neurology 158, 328-337 doi:10.1006/exnr.1999.7085
26. Dubois B. et al. (2016) Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimer’s & Dementia 12, 292-323 doi:10.1016/j.jalz.2016.02.002
27. Weksler M.E. et al. (2002) Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Experimental Gerontology 37, 943-948
28. Spencer B. and Masliah E. (2014) Immunotherapy for Alzheimer’s disease: past, present and future. Frontiers in Aging Neuroscience 6, 114 doi:10.3389/fnagi.2014.00114
29. Li Y. et al. (2013) Clinical trials of amyloid-based immunotherapy for Alzheimer’s disease: end of beginning or beginning of end? Expert Opinion on Biological Therapy 13, 1515-1522 doi:10.1517/14712598.2013.838555
30. Lemere C.A. (2013) Immunotherapy for Alzheimer’s disease: hoops and hurdles. Molecular Neurodegeneration 8, 36
31. Lannfelt L. et al. (2014) Perspectives on future Alzheimer therapies: amyloid-β protofibrils – a new target for immunotherapy with BAN2401 in Alzheimer’s disease. Alzheimer’s Research and Therapy 6, 16 doi:10.1186/alzrt246
32. Gilman S. et al. (2005) Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562
33. Sarazin M. et al. (2013) Immunotherapy in Alzheimer’s disease: do we have all the pieces of the puzzle? Biological Psychiatry 74, 329-332 doi:10.1016/j.biopsych.2013.04.011
34. Schneeberger A. et al. (2009) Development of AFFITOPE vaccines for Alzheimer’s disease (AD) – from concept to clinical testing. Journal of Nutrition Health and Aging 13, 264-267
35. Schneeberger A. et al. (2015) 12th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, Nice, France
36. Winblad B. et al. (2012) Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurology 11, 597-604 doi:10.1016/S1474-4422(12)70140-0
37. Kingwell K. (2012) Alzheimer disease: amyloid-β immunotherapy CAD106 passes first safety test in patients with Alzheimer disease. Nature Reviews Neurology 8, 414 doi: 10.1038/nrneurol.2012.128
38. Lannfelt L., Relkin N.R. and Siemers E.R. (2014) Amyloid-ßdirected immunotherapy for Alzheimer’s disease. Journal of Internal Medicine 275, 284-295 doi:10.1111/joim.12168
39. Arai H., Suzuki H. and Yoshiyama T. (2015) Vanutide Cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer’s disease: results from two phase 2 studies. Current Alzheimer Research 12, 242-254
40. Wang Y.J., Zhou H.D. and Zhou X.F. (2010) Modified immunotherapies against Alzheimer’s disease: toward safer and effective amyloid-β clearance. Journal of Alzheimer’s Disease 21, 1065-1075
41. Holliger P. and Hudson P.J. (2005) Engineered antibody fragments and the rise of single domains. Nature Biotechnology 23, 1126-1136
42. Waldmann T.A. (2003) Immunotherapy: past, present and future. Nature Medicine 9, 269-277 doi:10.1038/nm0303-269
43. Bard F. et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Medicine 6, 916-919
44. Salloway S. et al. (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. New England Journal of Medicine 370, 322-333 doi:10.1056/NEJMoa1304839
45. Sperling R.A. et al. (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimer’s & Dementia 7, 367-385 doi:10.1016/j.jalz.2011.05.2351
46. Black R. et al. (2009) Immunotherapy regimes dependent on ApoE status (US Patent) US 20090155256 A1
47. DeMattos R.B. et al. (2001) Peripheral anti-A beta antibody alters CNS and plasma Aβ clearance and decreases brain Aβburden in a mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America 98, 8850-8855 doi:10.1073/pnas.151261398
48. Doody R.S. et al. (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. New England Journal of Medicine 370, 311-321 doi:10.1056/NEJMoa1312889
49. Samadi H. and Sultzer D. (2011) Solanezumab for Alzheimer’s disease. Expert Opinion on Biological Therapy 11, 787-798 doi:10.1517/14712598.2011.578573
50. Fleisher A.S. et al. (2015) Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurology 72, 316-324 doi:10.1001/jamaneurol.2014.3314
51. Bohrmann B. et al. (2012) Gantenerumab: a novel human antiAβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. Journal of Alzheimer’s Diseases 28, 49-69 doi: 10.3233/JAD-2011-110977
52. Ostrowitzki S. et al. (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Archives of Neurology 69, 198-207 doi:10.1001/archneurol.2011.1538
53. Adolfsson O. et al. (2012) An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. Journal of Neuroscience 32, 9677-9689 doi:10.1523/JNEUROSCI.4742-11.2012
54. Crespi G.A.N. et al. (2015) Molecular basis for mid-region amyloid-β capture by leading Alzheimer’s disease immunotherapies. Science Report 5, 9649 doi:10.1038/srep09649
55. La Porte S.L. et al. (2012) Structural basis of C-terminal βamyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer’s disease. Journal of Molecular Biology 421, 525-536 doi:10.1016/j.jmb.2011.11.047
56. Tucker S. et al. (2015) The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. Journal of Alzheimer’s Disease 43, 575-588 doi:10.3233/JAD-140741
57. Lannfelt L. et al. (2014) Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease. Alzheimer’s Research and Therapy 6, 16 doi:10.1186/alzrt246
58. Popugaeva E. and Bezprozvanny I. (2014) Can the calcium hypothesis explain synaptic loss in Alzheimer’s disease? Neurodegenerative Disease 13, 139-141 doi:10.1159/000354778
59. Sevigny J. et al. (2015) 12th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, Nice, France
60. Underwood E. (2015) NEUROSCIENCE. Alzheimer’s amyloid theory gets modest boost. Science 349, 464 doi: 10.1126/science.349.6247.464
61. Reardon S. (2015) Antibody drugs for Alzheimer’s show glimmers of promise. Nature 523, 509-510 doi:10.1038/nature.2015.18031
62. Loeffler D.A. (2013) Intravenous immunoglobulin and Alzheimer’s disease: what now? Journal of Neuroinflammation 10, 70
63. Dodel R. et al. (2002) Human antibodies against amyloid β peptide: a potential treatment for Alzheimer’s disease. Annals of Neurology 52, 253-256
64. Weksler M.E., Pawelec G. and Franceschi C. (2009) Immune therapy for age-related diseases. Trends in Immunology 30, 344-350
65. Dodel R. et al. (2011) Naturally occurring autoantibodies against β-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer’s disease. Journal of Neuroscience 31, 5847-5854 doi:10.1523/JNEUROSCI.4401-10.2011
66. Istrin G., Bosis E. and Solomon B. (2006) Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-β peptide. Journal of Neuroscience Research 84, 434-443
67. Szabo P., Relkin N. and Weksler M.E. (2008) Natural human antibodies to amyloid beta peptide. Autoimmunity Reviews 7, 415-420
68. Klaver A.C. et al. (2010) Antibody concentrations to Aβ1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. International Immunopharmacology 10, 115-119
69. Boada M. et al. (2009) Amyloid-targeted therapeutics in Alzheimer’s disease: use of human albumin in plasma exchange as a novel approach for Aβ mobilization. Drug News & Perspectives 22, 325 doi:10.1358/dnp.2009.22.6.1395256
70. Dodel R. et al. (2010) Intravenous immunoglobulins as a treatment for Alzheimer’s disease: rationale and current evidence. Drugs 70, 513-528
71. Magga J. et al. (2010) Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer’s disease. Journal of Neuroinflammation 7, 90
72. MacHimoto T. et al. (2010) Effect of IVIG administration on complement activation and HLA antibody levels: ORIGINAL ARTICLE. Transplant International 23, 1015-1022
73. Abe Y. et al. (1994) Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunological Reviews 139, 5-19
74. Pigard N. et al. (2009) Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression. Journal of Neuroimmunology 209, 114-120
75. Kessel A. et al. (2007) Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. Journal of Immunology 179, 5571-5575
76. Schmidt A.M. et al. (2009) The role of RAGE in amyloid-β peptide-mediated pathology in Alzheimer’s disease. Current Opinion on Investigational Drugs 10, 672-680
77. Deane R. et al. (2003) RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nature Medicine 9, 907-913
78. Shibata M. et al. (2000) Clearance of Alzheimer’s amyloidβ1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. Journal of Clinical Investigation 106, 1489-1499
79. Deane R., Sagare A. and Zlokovic B.V. (2008) The role of the cell surface LRP and soluble LRP in blood–brain barrier Aβ clearance in Alzheimer’s disease. Current Pharmaceutical Design 14, 1601-1605
80. Sagare A. et al. (2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nature Medicine 13, 1029-1031
81. Tamura Y. et al. (2005) The F(ab)’2 fragment of an Aβ-specific monoclonal antibody reduces Abeta deposits in the brain. Neurobiology of Disease 20, 541-549 doi:10.1016/j.nbd.2005.04.007
82. Robert R. and Wark K.L. (2012) Engineered antibody approaches for Alzheimer’s disease immunotherapy. Archives of Biochemistry and Biophysics 526, 132-138
83. Liu R. et al. (2004) Single chain variable fragments against βamyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 43, 6959-6967 doi:10.1021/bi049933o
84. Frenkel D., Solomon B. and Benhar I. (2000) Modulation of Alzheimer’s β-amyloid neurotoxicity by site-directed single-chain antibody. Journal of Neuroimmunology 106, 23-31
85. Lafaye P. et al. (2009) Single-domain antibodies recognize selectively small oligomeric forms of amyloid β, prevent Aβ-induced neurotoxicity and inhibit fibril formation. Molecular Immunology 46, 695-704
86. Robert R. et al. (2009) Engineered antibody intervention strategies for Alzheimer’s disease and related dementias by targeting amyloid and toxic oligomers. Protein Engineering Design and Selection 22, 199-208
87. Habicht G. et al. (2007) Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils. Proceedings of the National Academy of Sciences of the United States of America 104, 19232-19237
88. Meli G. et al. (2009) Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer’s Amyloid-β oligomers. Journal of Molecular Biology 387, 584-606
89. Paganetti P. et al. (2005) β-site specific intrabodies to decrease and prevent generation of Alzheimer’s Aβ peptide. Journal of Cell Biology 168, 863-868
90. Rangan S.K. et al. (2003) Degradation of β-amyloid by proteolytic antibody light chains. Biochemistry 42, 14328-14334 doi:10.1021/bi035038d
91. Taguchi H. et al. (2008) Exceptional amyloid β peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. Journal of Biological Chemistry 283, 36724-36733
92. Taguchi H. et al. (2008) Catalytic antibodies to amyloid β peptide in defense against Alzheimer disease. Autoimmunity Reviews 7, 391-397
93. Kasturirangan S. and Sierks M. (2010) Targeted hydrolysis of β-amyloid with engineered antibody fragment. Current Alzheimer Research 7, 214-222
94. Giménez-Llort L. et al. (2013) Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease. MAbs 5, 665-677
95. Esquerda-Canals G. et al. (2013) Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid β antibody fragment. MAbs 5, 660-664 doi: 10.4161/mabs.25428
96. Kim D.Y. et al. (2014) Mutational approaches to improve the biophysical properties of human single-domain antibodies. Biochimica et Biophysica Acta – Proteins and Proteomics 1844, 1983-2001
97. Hamers-Casterman C. et al. (1993) Naturally occurring antibodies devoid of light chains. Nature 363, 446-448
98. Muyldermans S., Cambillau C. and Wyns L. (2001) Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends in Biochemical Sciences 26, 230-235
99. Paraschiv G. et al. (2013) Epitope structure and binding affinity of single chain llama anti-β-amyloid antibodies revealed by proteolytic excision affinity-mass spectrometry. Journal of Molecular Recognition 26, 1-9
100. Hanenberg M. et al. (2014) Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease. Journal of Biological Chemistry 289, 27080-27089 doi:10.1074/jbc.M114.564013
101. Binz H.K. et al. (2004) High-affinity binders selected from designed ankyrin repeat protein libraries. Nature Biotechnology 22, 575-582 doi:10.1038/nbt962
102. Binz H.K. et al. (2003) Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. Journal of Molecular Biology 332, 489-503
103. Stumpp M.T., Binz H.K. and Amstutz P. (2008) DARPins: a new generation of protein therapeutics. Drug Discovery Today 13, 695-701 doi:10.1016/j.drudis.2008.04.013
104. Amstutz P. et al. (2005) Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins. Journal of Biological Chemistry 280, 24715-24722 doi:10.1074/jbc.M501746200
105. Kohl A. et al. (2005) Allosteric inhibition of aminoglycoside phosphotransferase by a designed ankyrin repeat protein. Structure 13, 1131-1141 doi:10.1016/j.str.2005.04.020
106. Zahnd C. et al. (2010) Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Research 70, 1595-1605 doi: 10.1158/0008-5472.CAN-09-2724
107. Pike C.J. et al. (1991) In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Research 563, 311-314
108. Busciglio J., Lorenzo A. and Yankner B.A. (1992) Methodological variables in the assessment of βamyloid neurotoxicity. Neurobiology of Aging 13, 609-612
109. Cheng I.H. et al. (2007) Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. Journal of Biological Chemistry 282, 23818-23828 doi:10.1074/jbc.M701078200
110. Walsh D.M. and Selkoe D.J. (2007) Aβ oligomers – a decade of discovery. Journal of Neurochemistry 101, 1172-1184 doi: 10.1111/j.1471-4159.2006.04426.x
111. Horikoshi Y. et al. (2004) Aβ N-terminal-end specific antibody reduced β-amyloid in Alzheimer-model mice. Biochemistry and Biophysical Research Communications 325, 384-387
112. Bussière T. et al. (2004) Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβimmunotherapy on their clearance. American Journal of Pathology 165, 987-995
113. Lu J.-X. et al. (2013) Molecular structure of β-amyloid fibrils in Alzheimer’s disease brain tissue. Cell 154, 1257-1268 doi: 10.1016/j.cell.2013.08.035
114. Schenk D. et al. (1999) Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 doi:10.1038/22124
115. Wilcock D.M. et al. (2004) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. Journal of Neuroscience 24, 6144-6151 doi:10.1523/JNEUROSCI.1090-04.2004
116. Schlachetzki F., Zhu C. and Pardridge W.M. (2002) Expression of the neonatal Fc receptor (FcRn) at the blood–brain barrier. Journal of Neurochemistry 81, 203-206
117. Bacskai B.J. et al. (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. Journal of Neuroscience 22, 7873-7878
118. Das P. et al. (2003) Amyloid-β immunization effectively reduces amyloid deposition in FcR gamma-/- knock-out mice. Journal of Neuroscience 23, 8532-8538
119. Kou J. et al. (2011) Anti-amyloid-β single-chain antibody brain delivery via aav reduces amyloid load but may increase cerebral hemorrhages in an Alzheimer’s disease mouse model. Journal of Alzheimer’s Disease 27, 23-28
120. Wang Y.J. et al. (2009) Intramuscular delivery of a single chain antibody gene reduces brain Aβ burden in a mouse model of Alzheimer’s disease. Neurobiology of Aging 30, 364-376
121. Boado R.J. et al. (2013) Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. Biotechnology and Bioengineering 110, 1456-1465 doi: 10.1002/bit.24795
122. Kissel K. et al. (1998) Immunohistochemical localization of the murine transferrin receptor (TfR) on blood-tissue barriers using a novel anti-TfR monoclonal antibody. Histochemistry and Cell Biology 110, 63-72
123. Jefferies W.A. et al. (1984) Transferrin receptor on endothelium of brain capillaries. Nature 312, 162-163
124. Fishman J.B. et al. (1987) Receptor-mediated transcytosis of transferrin across the blood–brain barrier. Journal of Neuroscience Research 18, 299-304
125. Roberts R.L., Fine R.E. and Sandra A. (1993) Receptor-mediated endocytosis of transferrin at the blood–brain barrier. Journal of Cell Science 104(Pt 2), 521-532
126. Dufes C., Al Robaian M. and Somani S. (2013) Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Therpeutic Delivery 4(2041-5990 (Print)), 629-640 doi:10.4155/tde.13.21
127. Yu Y.J. and Watts R.J. (2013) Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics 10, 459-472
128. ′ cargo across the blood-brain barrier in mice. European Journal of Pharmaceutical Sciences 49, 556-564
129. Niewoehner J. et al. (2014) Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81, 49-60
130. Yu Y.J. et al. (2011) Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Science Translational Medicine 3, 84ra44
131. Shimada M. et al. (2013) Prophylaxis and treatment of Alzheimer’s disease by delivery of an Adeno-Associated virus encoding a monoclonal antibody targeting the amyloid β protein. PLoS ONE 8, e57606
132. Sudol K.L. et al. (2009) Generating differentially targeted amyloid-β specific intrabodies as a passive vaccination strategy for Alzheimer’s disease. Molecular Therapy 17, 2031-2040